ApnimedAPMD
NASDAQNo cached AI snapshot yet for APMD.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
— employees39.82M shares outstandinglisted 2026-07-31
About Apnimed
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
Latest News
Showing market-wide stock news
FOMC day
Bitcoin retreats after crypto bill setback, Fed next
This BlackRock strategist opposes a Fed hike. Here are the funds she recommends.
Gold outlook hinges on Fed signals; metal could test $4,200: Kotak Sec
US Dollar: Higher yields and oil support – MUFG
Bond Investors Are on Edge. Here's Why Stock Investors Should Pay Attention.
Related Stocks
Ready to see the live AI view on APMD?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing APMD side-by-side with live signals.